These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2802734)

  • 1. [Hormones in gynecologic oncology].
    Maass H
    Arch Gynecol Obstet; 1989; 245(1-4):466-73. PubMed ID: 2802734
    [No Abstract]   [Full Text] [Related]  

  • 2. Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
    Bonte J; Janssens JP; Ide P
    Eur J Gynaecol Oncol; 1986; 7(1):45-50. PubMed ID: 2938955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoma of the endometrium and hormonal receptors.
    Satyaswaroop PG; Zaino RJ; Mortel R
    Cancer Treat Res; 1989; 49():71-92. PubMed ID: 2577204
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in receptor status after treatment with tamoxifen in endometrial cancer.
    Oriana S; Raspagliesi F; Duca PG; Coradini D; Di Re EM; Ragazzi D; Grillo T; Luciani L
    Int J Biol Markers; 1988; 3(4):233-6. PubMed ID: 3235850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
    Thurzó L
    Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of hydroxyprogesterone caproate and its combination with tamoxifen on steroid hormone receptors in the tumor and on the basic parameters of reproductive homeostasis in patients with cancer of the corpus uteri].
    Vishnevskiĭ AS; Bokhman IaV; Tsyrlina EV; Bobrov IuF; Shtofmakher IA
    Vopr Onkol; 1989; 35(9):1063-7. PubMed ID: 2815695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy with single agents for advanced or recurrent endometrial carcinoma.
    Thigpen T
    Cancer Treat Res; 1989; 49():93-106. PubMed ID: 2577205
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tamoxifen-induced progesterone receptors in breast tumors].
    Tsyrlina EV; Semiglazov VF; Nurgaziev KSh; Ivanova OA
    Vopr Onkol; 1991; 37(9-10):916-21. PubMed ID: 1842650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Endocrine therapy of breast cancer].
    Jonat W; Maass H
    Zentralbl Gynakol; 1987; 109(10):617-27. PubMed ID: 2956805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen: an overview of recent studies in the field of oncology.
    Patterson JS; Battersby LA
    Cancer Treat Rep; 1980; 64(6-7):775-8. PubMed ID: 7000349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Megestrol acetate as hormone therapy in oncology].
    Berstein LM
    Vopr Onkol; 1998; 44(2):142-8. PubMed ID: 9615815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer--a commentary.
    Lippman ME
    Breast Cancer Res Treat; 1985; 6(3):195-200. PubMed ID: 3841498
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunohistochemical detection of progesterone receptors in primary breast cancer and lymph node metastases].
    Müller-Holzner E; Zeimet AG; Daxenbichler G; Marth C; Müller LC; Dapunt O
    Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():234-5. PubMed ID: 8118287
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Sem Hop; 1984 Mar; 60(10):703-9. PubMed ID: 6322320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breast cancer adjuvants: results of a DUR (drug utilization research) study].
    Nuzzo A
    Suppl Tumori; 2004; 3(4):S86-7. PubMed ID: 15206223
    [No Abstract]   [Full Text] [Related]  

  • 16. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J; Vandenberg TA
    Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of tamoxifen on the content of cytoplasmic steroid hormone receptors of the tumor in patients with cancer of the corpus uteri].
    Tsyrlina EV; Sofroniĭ DF; Dil'man VM; Bokhman IaV; Vishnevskiĭ AS
    Vopr Onkol; 1989; 35(6):675-80. PubMed ID: 2750079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy in node-negative breast cancer. A panel discussion.
    McGuire WL; Abeloff MD; Fisher B; Glick JH; Henderson IC; Osborne CK
    Breast Cancer Res Treat; 1989 Mar; 13(2):97-115. PubMed ID: 2659105
    [No Abstract]   [Full Text] [Related]  

  • 19. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.
    Ettinger DS; Allegra J; Bertino JR; Bonomi P; Browder H; Byrne P; Carpenter J; Catalano R; Creech R; Dana B
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):9-14. PubMed ID: 3026052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hormonal therapy in endometrial cancer].
    Piura B
    Harefuah; 1985 Jul; 109(1-2):11-3. PubMed ID: 4076887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.